Go Pro
→ Four winners over 400%. Here's #5 (From Golden Portfolio) (Ad)tc pixel Free BIIB Stock Alerts

Biogen (BIIB) Competitors

Biogen logo
$216.03 +14.07 (+6.97%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$215.50 -0.53 (-0.25%)
As of 06/26/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

Should you buy Biogen stock or one of its competitors? MarketBeat compares Biogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biogen include Amgen (AMGN), Denali Therapeutics (DNLI), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), and Moderna (MRNA). These companies are all part of the "medical" sector.

How does Biogen compare to Amgen?

Biogen (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.22$1.29B$9.3223.18
Amgen$36.75B5.27$7.71B$14.3724.96

In the previous week, Amgen had 16 more articles in the media than Biogen. MarketBeat recorded 27 mentions for Amgen and 11 mentions for Biogen. Amgen's average media sentiment score of 0.80 beat Biogen's score of 0.63 indicating that Amgen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Amgen
17 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive

Biogen has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Amgen has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

Biogen presently has a consensus target price of $217.37, suggesting a potential upside of 0.62%. Amgen has a consensus target price of $354.42, suggesting a potential downside of 1.17%. Given Biogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Biogen is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
12 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.57
Amgen
2 Sell rating(s)
15 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.43

87.9% of Biogen shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Amgen has a net margin of 20.96% compared to Biogen's net margin of 13.81%. Amgen's return on equity of 137.41% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen13.81% 12.83% 8.01%
Amgen 20.96%137.41%13.28%

Summary

Amgen beats Biogen on 13 of the 17 factors compared between the two stocks.

How does Biogen compare to Denali Therapeutics?

Biogen (NASDAQ:BIIB) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Biogen has a net margin of 13.81% compared to Denali Therapeutics' net margin of 0.00%. Biogen's return on equity of 12.83% beat Denali Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen13.81% 12.83% 8.01%
Denali Therapeutics N/A -52.20%-43.86%

Biogen has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

87.9% of Biogen shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biogen has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.22$1.29B$9.3223.18
Denali Therapeutics$330.53M12.28-$512.54M-$2.88N/A

Biogen presently has a consensus price target of $217.37, suggesting a potential upside of 0.62%. Denali Therapeutics has a consensus price target of $34.25, suggesting a potential upside of 33.95%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
12 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.57
Denali Therapeutics
1 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.81

In the previous week, Biogen had 9 more articles in the media than Denali Therapeutics. MarketBeat recorded 11 mentions for Biogen and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.94 beat Biogen's score of 0.63 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Denali Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Biogen beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Biogen compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Gilead Sciences has a net margin of 30.99% compared to Biogen's net margin of 13.81%. Gilead Sciences' return on equity of 48.19% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Gilead Sciences30.99% 48.19% 18.28%
Biogen 13.81%12.83%8.01%

Gilead Sciences currently has a consensus target price of $158.41, suggesting a potential upside of 23.89%. Biogen has a consensus target price of $217.37, suggesting a potential upside of 0.62%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Gilead Sciences is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilead Sciences
0 Sell rating(s)
4 Hold rating(s)
25 Buy rating(s)
0 Strong Buy rating(s)
2.86
Biogen
1 Sell rating(s)
12 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.57

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Gilead Sciences has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Biogen has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$29.44B5.39$8.51B$7.3417.42
Biogen$9.89B3.22$1.29B$9.3223.18

In the previous week, Gilead Sciences had 20 more articles in the media than Biogen. MarketBeat recorded 31 mentions for Gilead Sciences and 11 mentions for Biogen. Gilead Sciences' average media sentiment score of 1.38 beat Biogen's score of 0.63 indicating that Gilead Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gilead Sciences
25 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biogen
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Gilead Sciences beats Biogen on 13 of the 17 factors compared between the two stocks.

How does Biogen compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

In the previous week, Ionis Pharmaceuticals had 23 more articles in the media than Biogen. MarketBeat recorded 34 mentions for Ionis Pharmaceuticals and 11 mentions for Biogen. Biogen's average media sentiment score of 0.63 beat Ionis Pharmaceuticals' score of -0.03 indicating that Biogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ionis Pharmaceuticals
7 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biogen
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Ionis Pharmaceuticals presently has a consensus price target of $102.90, suggesting a potential upside of 26.76%. Biogen has a consensus price target of $217.37, suggesting a potential upside of 0.62%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
16 Buy rating(s)
2 Strong Buy rating(s)
2.90
Biogen
1 Sell rating(s)
12 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.57

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$1.06B12.68-$381.39M-$2.07N/A
Biogen$9.89B3.22$1.29B$9.3223.18

Ionis Pharmaceuticals has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Biogen has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Biogen has a net margin of 13.81% compared to Ionis Pharmaceuticals' net margin of -30.91%. Biogen's return on equity of 12.83% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals-30.91% -58.65% -10.07%
Biogen 13.81%12.83%8.01%

Summary

Ionis Pharmaceuticals and Biogen tied by winning 8 of the 16 factors compared between the two stocks.

How does Biogen compare to Moderna?

Biogen (NASDAQ:BIIB) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

87.9% of Biogen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.22$1.29B$9.3223.18
Moderna$1.94B13.73-$2.82B-$8.15N/A

Biogen has a net margin of 13.81% compared to Moderna's net margin of -143.55%. Biogen's return on equity of 12.83% beat Moderna's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen13.81% 12.83% 8.01%
Moderna -143.55%-26.64%-19.32%

Biogen presently has a consensus target price of $217.37, suggesting a potential upside of 0.62%. Moderna has a consensus target price of $37.13, suggesting a potential downside of 44.80%. Given Biogen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biogen is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
12 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.57
Moderna
5 Sell rating(s)
11 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.83

Biogen has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

In the previous week, Moderna had 12 more articles in the media than Biogen. MarketBeat recorded 23 mentions for Moderna and 11 mentions for Biogen. Biogen's average media sentiment score of 0.63 beat Moderna's score of 0.52 indicating that Biogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Moderna
9 Very Positive mention(s)
3 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Biogen beats Moderna on 13 of the 17 factors compared between the two stocks.

Get Biogen News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIIB vs. The Competition

Export
MetricBiogenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$31.89B$3.63B$7.04B$12.19B
Dividend YieldN/A2.21%2.66%6.24%
P/E Ratio23.1821.5626.1324.17
Price / Sales3.22334.27600.51118.90
Price / Cash9.54141.1447.9555.62
Price / Book1.748.3310.786.36
Net Income$1.29B$23.91M$3.58B$337.99M
7 Day Performance9.89%3.42%2.22%0.10%
1 Month Performance10.00%0.39%-0.09%-1.28%
1 Year Performance71.34%65.22%34.39%27.68%

Biogen Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIIB
Biogen
2.9931 of 5 stars		$216.03
+7.0%		$217.37
+0.6%		+71.3%$31.89B$9.89B23.187,500
AMGN
Amgen
3.5175 of 5 stars		$344.72
+2.1%		$354.42
+2.8%		+29.4%$186.05B$37.22B23.9931,500
DNLI
Denali Therapeutics
3.07 of 5 stars		$24.05
+3.2%		$34.25
+42.4%		+81.3%$3.82B$330.53MN/A430
GILD
Gilead Sciences
4.9822 of 5 stars		$124.87
+0.9%		$158.41
+26.9%		+15.5%$155.03B$29.74B17.0117,000
IONS
Ionis Pharmaceuticals
2.8899 of 5 stars		$75.89
+2.4%		$101.80
+34.1%		+104.0%$12.54B$1.06BN/A1,402

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BIIB) was last updated on 6/28/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Are we ignoring the same signal Wall Street ignored in 1929?
In 1929, a 20-something broker named Irving Weiss shorted the market before Black Monday and made a fortune. H...
Weiss Ratings | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Four winners over 400%. Here's #5
CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...
Golden Portfolio | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Elon Musk, Larry Fink & Brian Armstrong are ALL Piling into This
Elon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...
Brownstone Research | Sponsoredtc pixel
They proved it worked in '76. Then buried it.
In 1976, Chevron, Unocal, and Texaco each confirmed the same energy technology worked - no fuel costs, no carb...
Behind the Markets | Sponsoredtc pixel